09.01.20 -- New Podcast Episodes: Bolt Biotherapeutics On Fundraising; RNAi Beyond The Liver; Myeloid Cells In Immuno-Oncology

Check out the latest from Business of Biotech, Biotech with the Bozenhardts, and Life Science Connect. As a member of the Life Science Connect community you have access to content beyond our weekly newsletters, including our podcast series. Don’t forget to subscribe so that you never miss an episode!

Dr. Randy Schatzman, CEO at Bolt Biotherapeutics, discusses his company's adjustment to pandemic disruption on the fundraising trail. He walks us through the remote fundraising strategy that landed Bolt a recent $93.5 million Series C financing round, as well as how the company is moving toward an IPO in spite of market, civil, and political tumult.

OSE Immunotherapeutics CEO Alexis Peyroles joins The Business Of Biotech – Summer Executive Sessions to discuss the role of myeloid cells in immunology, why a team of transplant specialists is key to his company's therapeutic development approach, and how he is creating differentiation as a clinical-stage immunotherapy company in an ever-growing sea of competitors.

Arrowhead Pharma CEO Christopher Anzalone, Ph.D., gives us the inside story on the stake his company claimed on the now reburgeoning RNAi space, the indications his company is targeting beyond liver disease, and how it's addressing the development and process challenges that must be overcome to further progress RNAi beyond the liver.

Herman and Erich Bozenhardt have a collective 55 years of bioprocess facilities design and equipment experience, and they’re here to share it all in our fresh Bioprocess with the Bozenhardts podcast series.

Editorial director Dan Schell catches up with the talented and passionate group of Life Science Connect editors who cover a broad spectrum of the pharmaceutical and biotech industries for informal discussions about interesting topics and some of the interviews they’ve had recently.